Status:
COMPLETED
RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration
Lead Sponsor:
Maturi, Raj K., M.D., P.C.
Conditions:
Age Related Macular Degeneration
Eligibility:
All Genders
50-99 years
Phase:
PHASE1
PHASE2
Brief Summary
This study is a single-center, open label, 4-month study, designed to evaluate the safety and treatment efficacy of RBM-007 in patients with intraretinal or subretinal edema due to previously untreate...
Eligibility Criteria
Inclusion
- • General
- Male or female patients, 50 years of age or older at baseline
- Patient has completed/signed an informed consent prior to any study-related procedures and is able to follow study instructions and likely to complete all required visits.
- • Ocular
- Best Corrected Visual Acuity (BCVA) 5 - 73 ETDRS letters (20/800-20/40 Snellen equivalent), inclusive, in study eye
- Presence of choroidal neovascularization secondary to AMD
- Clear ocular media and adequate pupil dilation to permit good quality photographic imaging.
Exclusion
- • General
Key Trial Info
Start Date :
June 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 4 2022
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT04895293
Start Date
June 15 2021
End Date
March 4 2022
Last Update
April 12 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Midwest Eye Institute
Indianapolis, Indiana, United States, 46290